KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's Net Income towards Common Stockholders rose 6080.52% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 4489.46%. This contributed to the annual value of -$69.9 million for FY2024, which is 402.06% up from last year.
  • Arbutus Biopharma's Net Income towards Common Stockholders amounted to -$7.7 million in Q3 2025, which was up 6080.52% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Net Income towards Common Stockholders peaked at $2.5 million during Q2 2025, and registered a low of -$24.5 million during Q1 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$19.3 million (2023), whereas its average is -$17.4 million.
  • The largest annual percentage gain for Arbutus Biopharma's Net Income towards Common Stockholders in the last 5 years was 11264.4% (2025), contrasted with its biggest fall of 3733.06% (2025).
  • Quarter analysis of 5 years shows Arbutus Biopharma's Net Income towards Common Stockholders stood at -$21.9 million in 2021, then dropped by 0.17% to -$21.9 million in 2022, then increased by 11.95% to -$19.3 million in 2023, then surged by 35.28% to -$12.5 million in 2024, then skyrocketed by 38.16% to -$7.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$7.7 million for Q3 2025, versus $2.5 million for Q2 2025 and -$24.5 million for Q1 2025.